25 results on '"Crook J"'
Search Results
2. The role of radiotherapy in the management of squamous cell cancer of the penis.
- Author
-
Crook J
- Subjects
- Humans, Male, Combined Modality Therapy, Neoplasm Staging, Penis pathology, Brachytherapy methods, Carcinoma, Squamous Cell pathology, Penile Neoplasms pathology
- Abstract
Purpose: To review the evidence for radiotherapy in the management of primary penile cancer, either as brachytherapy or external beam radiation, and the role of external beam radiotherapy in node positive penile cancer., Methods: English language literature was reviewed for the past 3 decades. As penile cancer is uncommon in developed nations, high quality evidence to guide management is limited. Single institution reports often span decades during which time staging systems and treatments have evolved, reducing their relevance to current practice. Successful clinical trials require collaboration not only among disciplines but also among multiple institutions and nations., Results: Radiotherapy is a definitive organ-preserving option for T1-T2 penile cancers. Interstitial brachytherapy is associated with penile preservation in 85% of men at 5 years, maintained in 70% by 10 years. Results of external radiotherapy are not quite as promising but nonetheless 60% of men will have an intact penis at 5 years. Inguino-pelvic external radiotherapy has been reported to increase overall survival when delivered as adjuvant treatment for men with pN3 groin but pN0 pelvic nodes, and improve disease specific survival for those with involved pelvic nodes. InPACT (ECOG-ACRIN_8134) is investigating the role of inguino-pelvic chemo-radiotherapy for men with pN3 inguinal nodes but imaging negative pelvic nodes., Conclusions: Radiotherapy has a well-defined role to play in treatment of squamous cell cancers of other sites, such as vulva, anal canal, uterine cervix and head and neck malignancies. Emerging data support the incorporation of radiotherapy into treatment paradigms for penile cancer., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
3. High-dose-rate brachytherapy for localized penile cancer: Evolution of a technique.
- Author
-
Marbán M, Crook J, Keyes M, Dubash R, and Batchelar D
- Subjects
- Adult, Aged, Brachytherapy adverse effects, Carcinoma, Squamous Cell pathology, Disease-Free Survival, Humans, Male, Middle Aged, Necrosis etiology, Neoplasm Staging, Penile Neoplasms pathology, Penis pathology, Radiotherapy Dosage, Urethral Stricture etiology, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Neoplasm Recurrence, Local surgery, Penile Neoplasms radiotherapy
- Abstract
Purpose: High-dose-rate (HDR) brachytherapy is a convenient treatment option for selected patients with T1-T2 penile squamous cell carcinoma (SCC), providing high rates of penile preservation and tumor control. We present the results of penile SCC treated with HDR brachytherapy either interstitially or via a surface mold., Methods and Materials: Between November 2009 and April 2019, seven patients (2 T1a and 5 T2) were treated with interstitial HDR and 8 (1 Tis, six T1a, and one T1b) with surface mold. Prescribed dose for interstitial patients ranged from 38.4 Gy in 6 days (3.2 Gy × 12) to 53 Gy in 9 days (3.12 × 17), BID. All patients treated with mold brachytherapy received 40 Gy in 10 fractions BID. Toxicity and oncological results were assessed for both groups, and their relation with dosimetry is described., Results: Median follow up was 90 months for interstitial and 27 months for those treated with surface mold. Fourteen of 15 patients are alive and disease-free; one surface mold patient died of non-small-cell lung cancer. There was one relapse in each group, each treated with salvage penectomy. The potency was preserved in 82%. For interstitial, G2 necrosis occurred in 43%, G2 meatal stenosis in 29% and G3 stenosis in 14%., Conclusions: Both techniques have excellent rates of tumor control and organ preservation. Implant geometry and homogeneity constraints must be carefully designed to minimize toxicity in interstitial brachytherapy. Urethral contouring and reporting of dosimetric parameters should be defined., (Copyright © 2019 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
4. Contemporary Role of Radiotherapy in the Management of Primary Penile Tumors and Metastatic Disease.
- Author
-
Crook J
- Subjects
- Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell secondary, Combined Modality Therapy, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Penile Neoplasms pathology, Brachytherapy methods, Carcinoma, Squamous Cell surgery, Disease Management, Penile Neoplasms radiotherapy
- Abstract
Squamous cell cancer of the penis is a radiocurable malignancy all too often managed solely by partial or total penectomy. Effective management of the primary tumor while preserving penile morphology and function is a priority. External radiotherapy and brachytherapy have a role to play in the definitive management of the primary tumor. Surgical nodal staging remains a cornerstone of management because it is the strongest predictor of survival, and inguinal status determines pelvic management. Postoperative radiotherapy of the regional nodes for high-risk pathology is indicated. Chemoradiotherapy should be considered as neoadjuvant treatment for unresectable nodes or as definitive management., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
5. The role of radiotherapy in the management of penile cancer.
- Author
-
Crook J
- Subjects
- Brachytherapy methods, Humans, Male, Neoplasm, Residual, Palliative Care methods, Radiotherapy, Adjuvant methods, Carcinoma, Squamous Cell radiotherapy, Penile Neoplasms radiotherapy
- Published
- 2015
- Full Text
- View/download PDF
6. The efficacy of hyperbaric oxygen therapy in the treatment of medically refractory soft tissue necrosis after penile brachytherapy.
- Author
-
Gomez-Iturriaga A, Crook J, Evans W, Saibishkumar EP, and Jezioranski J
- Subjects
- Adult, Aged, Humans, Male, Middle Aged, Necrosis, Radiotherapy Dosage, Carcinoma, Squamous Cell radiotherapy, Hyperbaric Oxygenation, Penile Neoplasms radiotherapy, Radiation Injuries therapy, Skin pathology
- Abstract
Purpose: Soft tissue necrosis is reported in up to 26% of patients undergoing radiotherapy for penile cancer. Management options include local irrigation, wound debridement, antibiotics, anti-inflammatory medication, and analgesics. Refractory lesions may be treated with partial penectomy. Hyperbaric oxygen therapy (HBO) has a well-defined role in the treatment of late radiation toxicities. We present experience with HBO for medically refractory soft tissue necrosis after penile brachytherapy., Methods and Materials: From November 2001 to January 2009, 7 men of 43 treated with penile brachytherapy for squamous carcinoma developed refractory soft tissue necrosis and were treated with HBO. All had received a prescribed dose of 60 Gy through interstitial brachytherapy using Paris system guidelines. All had failed conservative medical therapies for soft tissue necrosis., Results: Median age was 55 years (range, 35-72 years). Comorbidities potentially effecting wound healing included hypertension (2), current smokers (5), former smoker (1) but no diabetes mellitus, or peripheral vascular disease. Median time between completion of brachytherapy and appearance of soft tissue necrosis was 13 months (range, 9-24 months) and the median interval before starting HBO was 7.5 months (range, 3-13 months). The median number of "dives" per HBO course was 40 (30-53). All 7 experienced an excellent response with healing of the necrosis and resolution of symptoms, although 3 required an additional course, 2 for consolidation of healing, and 1 for a relapse 4 months later. No patient was submitted to penectomy., Conclusions: HBO should be considered as a treatment option in patients with refractory soft tissue necrosis of the penis after brachytherapy., (Copyright © 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
7. Penile brachytherapy: technical aspects and postimplant issues.
- Author
-
Crook J, Jezioranski J, and Cygler JE
- Subjects
- Carcinoma, Squamous Cell diagnosis, Humans, Male, Penile Neoplasms diagnosis, Treatment Outcome, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Penile Neoplasms radiotherapy
- Abstract
Purpose: Squamous carcinoma (SCC) of the penis affects about 1 in 100,000 men in western societies. Interstitial brachytherapy can be an effective penis-conserving modality for T1, T2, and selected T3 tumors. Unfortunately, few radiation oncology trainees have the opportunity to treat a case of penile cancer during their residency, and few centers have brachytherapy expertise for this tumor site. We report our technique that has been developed and refined over the past 20 years., Materials and Methods: From 1989 to 2009, we have been using brachytherapy to treat penile SCC and have experience with 75 cases. From 1989 to 1998, manual afterloading was used with (192)Ir wire or seeds, and from 1999 to the present, pulse dose rate automated afterloading. Sixty Gray is delivered over a period of 4-5 days., Results: Patient selection for penile brachytherapy and the technical and dosimetric aspects of the procedure will be discussed along with posttreatment care and followup., Conclusions: Brachytherapy is an effective treatment for T1, T2, and selected T3 SCC of the penis. Efficacy depends on careful planning and appreciation of dosimetry., ((c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
8. Multimodality therapy in penile cancer: when and which treatments?
- Author
-
Pagliaro LC and Crook J
- Subjects
- Algorithms, Combined Modality Therapy, Humans, Male, Carcinoma, Squamous Cell therapy, Penile Neoplasms therapy
- Abstract
Objectives: Metastatic penile cancer typically comes to attention while the clinical extent of disease is limited to the inguinal or pelvic lymph nodes. Primary surgical management of lymph node metastases achieves tumor control and long-term survival for only a small percentage of these patients. To determine the optimal use of multimodality treatment in locally advanced penile cancer, we conducted a literature review., Methods: Relevant English-language literature was identified with the use of Medline; additional cited works not detected on the initial search were also reviewed., Results: There is an emerging strategy of preoperative (neoadjuvant) combination chemotherapy to improve the progression-free survival of penile cancer patients with bulky regional lymph node metastases. Radiotherapy for inguinal metastases and postoperative (adjuvant) radiation for selected patients has also been effective in this setting., Conclusions: In patients with lymph node metastases, the benefit of ilioinguinal lymphadenectomy may be extended by the addition of neoadjuvant chemotherapy. Postoperative radiotherapy can be offered depending on the amount of residual disease after chemotherapy. Chemo-radiotherapy has been successful in squamous cell cancers from other sites (vulva and anal canal) and may be considered for unresectable penile cancer.
- Published
- 2009
- Full Text
- View/download PDF
9. Radiation therapy in the management of the primary penile tumor: an update.
- Author
-
Crook J, Ma C, and Grimard L
- Subjects
- Adult, Aged, Aged, 80 and over, Follow-Up Studies, Humans, Male, Middle Aged, Young Adult, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Penile Neoplasms radiotherapy
- Abstract
Objectives: Squamous carcinoma of the penis is rare but psychologically devastating and potentially fatal. Radiotherapy offers a penile-conserving treatment option without jeopardizing cure. We have used primary penile brachytherapy as the treatment of choice for T1, T2 and selected T3 patients since 1989 and present updated results for 67 patients., Methods: Mean age was 60 years (range 22-93). Stage was T1 in 56%, T2: 33%, T3: 8%, and Tx: 3%. Grade was moderate or poorly differentiated in 48%. In Toronto after-loading pulse dose rate (PDR) brachytherapy (n = 41) was used for all treatments while Ottawa used manually loaded Iridium(192) (n = 26). Two or three parallel planes of needles (median 6) were inserted using pre-drilled lucite templates for guidance and fixation; 60 Gy was delivered over 4-5 days., Results: Median follow-up is 4 years (range 0.2-16.2). At 10 years, actuarial overall survival is 59%, cause specific survival 83.6%. Nine men died of penile cancer and eight of other causes with no evidence of recurrence. Penectomy was required for eight local failures and two necroses, for an actuarial penile preservation rate at 5 years of 88% and 10 years of 67%. The soft tissue necrosis rate is 12% and the urethral stenosis rate 9%. Six of 11 regional failures were salvaged by lymph node dissection +/- external radiation. The other five all had concurrent distant failure and died of disease., Conclusions: Brachytherapy is an effective treatment for T1, T2 and selected T3 SCC of the penis. Close follow-up is mandatory as local failures and many regional failures can be salvaged by surgery.
- Published
- 2009
- Full Text
- View/download PDF
10. Interstitial brachytherapy for penile cancer: an alternative to amputation.
- Author
-
Crook J, Grimard L, Tsihlias J, Morash C, and Panzarella T
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Humans, Male, Middle Aged, Orchiectomy, Penile Neoplasms mortality, Penile Neoplasms pathology, Penile Neoplasms surgery, Radiotherapy Dosage, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Penile Neoplasms radiotherapy
- Abstract
Purpose: Interstitial brachytherapy is an effective organ sparing treatment for localized penile squamous cell carcinoma. We report results in 30 patients., Materials and Methods: From September 1989 to November 2000, 30 men with penile squamous cell carcinoma were treated with primary brachytherapy. Tumor size was 2 to 3 cm. in 8 and greater than 3 cm. in 14 (maximum 5 cm.). Tumor was well differentiated in 11 patients, moderately in 10, poorly in 2 and unspecified in 6. Histology was verrucous in 1 patient. All implants complied with the Paris system of dosimetry, 26 of 30 with rigid steel needles held in a 3-dimensional array. The prescribed dose was 60 Gy. delivered at an average dose rate of 68 cGy. hourly for an implant duration of 93 hours., Results: Median followup was 34 months. There have been 4 local failures yielding an actuarial local failure-free rate of 85% at 2 years (standard error 8%) and 76% at 5 years (11%). Each local failure was salvaged with penectomy (partial in 2 cases). There have been 4 isolated regional failures, involving 1 to 3 nodes, 3 moderately and 1 poorly differentiated, salvaged with groin dissection. Two patients with moderately differentiated T1 squamous cell carcinoma who died of metastatic disease after inoperable regional and subsequent distant failure. No well differentiated tumors failed regionally or distantly. Three men died of other causes with no evidence of recurrence. Function and cosmesis after implantation have been generally good. Some telangiectasia and pigmentation changes were common. Two men complained of loss of potency, 3 required dilatation for meatal stenosis and 1 underwent partial penectomy for radiation necrosis., Conclusions: Brachytherapy provides excellent local control of T1 to T2 penile squamous cell carcinoma, with only 1 of 30 patients requiring partial penectomy for radionecrosis. Despite excellent local control, 50% of moderately or poorly differentiated tumors recurred distantly or regionally. We recommend planned staging superficial inguinal node dissection 3 months after implantation for moderately and/or poorly differentiated tumors with clinically negative groins.
- Published
- 2002
- Full Text
- View/download PDF
11. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.
- Author
-
Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, and Jones KD
- Subjects
- Adenocarcinoma blood, Adenocarcinoma therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Blood Transfusion, Carcinoma, Squamous Cell blood, Carcinoma, Squamous Cell therapy, Cisplatin therapeutic use, Combined Modality Therapy, Female, Fluorouracil therapeutic use, Follow-Up Studies, Humans, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Survival Analysis, Uterine Cervical Neoplasms blood, Uterine Cervical Neoplasms therapy, Adenocarcinoma radiotherapy, Carcinoma, Squamous Cell radiotherapy, Hemoglobins metabolism, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background: It is unclear whether blood transfusion can overcome the negative impact of anemia before or during radiotherapy (RT) in patients with carcinoma of the cervix. The objective of this retrospective study was to examine the impact of anemia and blood transfusion on 605 patients with carcinoma of the cervix treated with radical RT at 7 centers across Canada in 1989, 1990, and 1992., Methods: The data collected included hemoglobin (Hgb) levels from the time of diagnosis to the end of therapy; blood transfusions administered; and identifiable patient-, tumor-, and treatment-related factors. Survival, disease free survival, and pelvic control analyses were evaluated by univariate and multivariate analysis., Results: The median follow-up was 41 months (range, 0-92 months). Presenting Hgb level, average weekly nadir Hgb (AWNH) during RT, and blood transfusion were correlated significantly with local control, disease free survival, and overall survival on univariate analysis. However, the AWNH remained significant on multivariate analysis, whereas Hgb at presentation and blood transfusion did not. The 5-year survival was 74% for patients with an AWNH >/= 120 g/L, 52% for patients with AWNH levels 110-119 g/L inclusive, and 45% for patients with AWNH levels < 110 g/L (P < 0.0001). At each Hgb level, patients who were transfused and maintained a specific Hgb level had a survival rate that was not significantly different from patients who were at that level spontaneously. There was a significant reduction in both pelvic and distant recurrence (P < 0.0001 and P < 0.0006, respectively) in patients whose AWNH level during RT was >/= 120 g/L compared with < 120 g/L. A reduction in the rate of distant recurrence was observed in patients with and without pelvic recurrence., Conclusions: AWNH is highly predictive of outcome for patients treated with RT for carcinoma of the cervix. Blood transfusion appears to overcome the negative prognostic effects of low presenting Hgb levels and AWNH levels., (Copyright 1999 American Cancer Society.)
- Published
- 1999
- Full Text
- View/download PDF
12. Effect of intersource spacing on local control and complications in brachytherapy of mobile tongue and floor of mouth.
- Author
-
Simon JM, Mazeron JJ, Pohar S, Le Péchoux C, Crook JM, Grimard L, Piedbois P, Le Bourgeois JP, and Pierquin B
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy adverse effects, Female, Humans, Iridium Radioisotopes therapeutic use, Male, Middle Aged, Mouth Floor, Necrosis, Neoplasm Recurrence, Local, Treatment Failure, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Mouth Neoplasms radiotherapy, Tongue Neoplasms radiotherapy
- Abstract
From 1971 to 1988, 133 T1 and 141 T2 biopsy-proven squamous cell carcinomas of mobile tongue and floor of mouth were definitively managed by Iridium-192. Implantations were performed using either guide gutters or afterloading plastic catheters. The prescribed dose at the reference isodose (85% of the basal dose rate, Paris system) was 60-70 Gy. Total dose was not adjusted to dose rate or tumor volume. Results of the 274 implants have been analysed to look for a possible influence of intersource spacing on local control and necrosis. Follow up for patients free of local recurrence is 1-180 months with median of 35 months. The 274 tumors were divided into two groups according to intersource spacing: 9-14 mm (n = 204), and 15-20 mm (n = 70). At 5 years, the estimated local control (Kaplan Meier) was 86% and 76%; respectively (p = 0.13); the necrosis rate was 33% and 46%, respectively (p = 0.04). Multivariate analysis shows that dose and activity of wires were significantly related to local control, while only tumor site was predictive of necrosis; there was a non-statistically significant relationship between intersource spacing of wires and local control (p = 0.055). When considering only patients with oral tongue cancers, necrosis was significantly related to activity of wires (p = 0.013), and there was a non-significant trend to a relationship between necrosis and intersource spacing (p = 0.066) and tumor diameter (p = 0.065). For patients with floor of mouth cancer, none of these factors was significantly related to necrosis.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993
- Full Text
- View/download PDF
13. Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192.
- Author
-
Mazeron JJ, Simon JM, Le Péchoux C, Crook JM, Grimard L, Piedbois P, Le Bourgeois JP, and Pierquin B
- Subjects
- Carcinoma, Squamous Cell pathology, Dose-Response Relationship, Radiation, Humans, Iridium Radioisotopes administration & dosage, Iridium Radioisotopes adverse effects, Mouth Floor pathology, Mouth Floor radiation effects, Mouth Neoplasms pathology, Multivariate Analysis, Necrosis etiology, Necrosis pathology, Radiation Injuries, Tongue Neoplasms pathology, Carcinoma, Squamous Cell radiotherapy, Iridium Radioisotopes therapeutic use, Mouth Neoplasms radiotherapy, Radiotherapy Dosage, Tongue Neoplasms radiotherapy
- Abstract
From 1971 to 1988, 134 T1 and 145 T2 biopsy-proven squamous cell carcinomas of mobile tongue and floor of mouth were definitively managed by iridium-192. Implantations were performed using either guide gutters or afterloading plastic catheters. The prescribed dose at the reference isodose (85% of the basal dose rate, Paris system) was 60-70 Gy. Total dose was not adjusted to dose rate or tumor volume. Results of the 279 implants have been analysed to look for a possible influence of dose rate on local control and necrosis. Follow-up patients free of local recurrence is 1-180 months with average of 51 months. The 279 tumors were divided in four groups according to dose and dose rate: greater than or equal to 62.5 Gy and greater than or equal to 0.5 Gy/h (n = 130), greater than or equal to 62.5 Gy and less than 0.5 Gy/h (n = 36), less than 62.5 Gy and greater than or equal to 0.5 Gy/h (n = 81), less than 62.5 Gy and less than 0.5 Gy/h (n = 32). The four groups were comparable according to age, sex, tumor diameter and macroscopic aspect. At 5 years, the estimated local control (Kaplan Meier) was 93, 87, 79 and 52%, respectively (dose adjusted to dose rate: p less than 0.001, dose rate adjusted to dose: p less than 0.01, Log-rank); the necrosis rate was 44, 24, 37 and 5%, respectively (dose adjusted to dose rate: p = 0.08, dose rate adjusted to dose: p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1991
- Full Text
- View/download PDF
14. Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue.
- Author
-
Mazeron JJ, Crook JM, Benck V, Marinello G, Martin M, Raynal M, Haddad E, Peynègre R, Le Bourgeois JP, and Walop W
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Female, Humans, Male, Middle Aged, Radiotherapy adverse effects, Radiotherapy Dosage, Survival Rate, Tongue Neoplasms mortality, Tongue Neoplasms pathology, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Iridium Radioisotopes therapeutic use, Tongue Neoplasms radiotherapy
- Abstract
Between 1970 and 1986, 166 patients with T1 or T2 epidermoid carcinomas of the mobile tongue were treated by iridium 192 implantation (70 T1N0, 83 T2N0, 13 T1-2 N1-3). Five-year actuarial survival was 52% for T1N0, 44% for T2aN0, and 8% for or T1-2 N1-3. Cause specific survivals were 90%, 71%, and 46%, respectively. Local control was 87% for both T1N0 and T2N0, and 69% for T1-2 N1-3. Seven of 23 failures were salvaged by surgery, increasing local control to 96% for T1 and 90% for T2. Thirty-six patients developed a minor or moderate necrosis (16% T1, 28% T2). Half of these involved bone but only five required surgical intervention. Both local control (LC) and necrosis (nec) increased with increasing dose but improvement beyond 65 Gy is minimal (less than or equal to 60 Gy: LC = 78% nec = 13%; 65 Gy: LC = 90% nec = 29%; greater than or equal to 70 Gy: LC = 94% nec = 23%). For N0 patients, neck management consisted of surveillance (n = 78), elective neck dissection followed with external irradiation for pathologically positive nodes (n = 72), or irradiation (n = 3). Clinically positive nodes (13 patients) were managed by either neck dissection followed by external irradiation if pathologically positive (n = 10) or irradiation alone (n = 3). Regional control was 79% for N0 patients, improving to 88% after surgical salvage, and was 9/13 for N1-3 patients. We recommend that T1 and T2 carcinomas of the mobile tongue be treated by iridium 192 implantation to deliver 65 Gy. Mandibular necrosis should be reduced by using an intra-oral lead-lined dental mold.
- Published
- 1990
- Full Text
- View/download PDF
15. Comparison of curietherapy versus external irradiation combined with curietherapy in stage II squamous cell carcinomas of the mobile tongue.
- Author
-
Benk V, Mazeron JJ, Grimard L, Crook J, Haddad E, Piedbois P, Calitchi E, Raynal M, Martin M, and Le Bourgeois JP
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell physiopathology, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Movement, Necrosis etiology, Neoplasm Staging, Radiotherapy adverse effects, Retrospective Studies, Survival Rate, Tongue Neoplasms pathology, Tongue Neoplasms physiopathology, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Tongue Neoplasms radiotherapy
- Abstract
One hundred and ten patients with Stage II epidermoid carcinomas of the mobile tongue were treated by interstitial irradiation (Group I: 85 patients) or external irradiation to the primary and the regional lymphatics followed by an interstitial boost (Group II: 25 patients). The neck was managed by either an elective neck dissection (43 patients) completed by external irradiation in 13 patients with pathological specimen or close follow-up (40 patients) with therapeutic neck dissection for relapses (7 patients) in Group I. Primary local control was 88% in Group I and 36% in Group II. Regional control was 91% in Group I and 5/6 in Group II for patients whose primary tumor was controlled. Five-year absolute disease-free survival (DFS) was 42% in Group I and 24% in Group II, but there was an imbalance in the distribution of larger tumors favoring Group I. There were 30 radiation-induced complications and four patients required corrective surgery. This retrospective analysis showed better results in patients whose primary was treated by interstitial irradiation alone which has the extra advantage of preserving salivary function.
- Published
- 1990
- Full Text
- View/download PDF
16. Prognostic factors of local outcome for T1, T2 carcinomas of oral tongue treated by iridium 192 implantation.
- Author
-
Mazeron JJ, Crook JM, Marinello G, Walop W, and Pierquin B
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Carcinoma, Squamous Cell epidemiology, Female, France epidemiology, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local epidemiology, Prognosis, Radiotherapy Dosage, Retrospective Studies, Sex Factors, Tongue Neoplasms epidemiology, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Iridium Radioisotopes therapeutic use, Tongue Neoplasms radiotherapy
- Abstract
The results of Iridium 192 implantation for 121 node negative T1 or T2 squamous carcinomas of mobile tongue were reviewed to look for predictors of local control and necrosis. Age, sex, total dose, dose rate, linear activity, and intersource spacing were examined. Minimum follow-up was 2 years but no patient with local recurrence or necrosis was excluded. There were 57 T1N0 tumors, 45 T2aN0 (2.1-3.0 cm), and 19 T2bN0 (3.1-4.0 cm). Local failures occurred in 14% of T1, 11% of T2a, and 26% of T2b. Univariate analysis showed that local control increased with increasing dose (55-60 Gy: 73%; 65-75 Gy: 92%, p = 0.005), whereas multivariate analysis revealed both sex and total dose to be significant. Radiation necrosis occurred in 17% of T1, 29% of T2a, and 47% of T2b (p = 0.034). Half were limited to soft tissue and the majority healed with conservative management. Univariate analysis showed that necrosis increased with increasing dose (55-60 Gy: 16%; 65-75 Gy: 33%, p = 0.037), as well as increasing dose rate, linear activity, and intersource spacing. With multivariate analysis only stage, dose rate, and spacing remained predictive of necrosis. Total dose was not adjusted for dose rate or tumor volume. This analysis suggests that within the therapeutic range of low dose rate brachytherapy, correction of total dose according to dose rate is unnecessary. We recommend 65 Gy. Lower dose rate (0.4-0.5 Gy/hr) and closer intersource spacing (12-14 mm) should be aimed for to minimize necrosis.
- Published
- 1990
- Full Text
- View/download PDF
17. Effect of dose rate on local control and necrosis in the reirradiation of faucial arch squamous cell carcinomas with interstitial iridium 192.
- Author
-
Mazeron JJ and Crook JM
- Subjects
- Carcinoma, Squamous Cell mortality, Humans, Mouth Neoplasms mortality, Mouth Neoplasms radiotherapy, Necrosis, Pharyngeal Neoplasms mortality, Radiation Injuries etiology, Radiation Injuries pathology, Brachytherapy adverse effects, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Iridium therapeutic use, Pharyngeal Neoplasms radiotherapy
- Published
- 1990
- Full Text
- View/download PDF
18. Interstitial iridium 192 for cutaneous carcinoma of the external nose.
- Author
-
Crook JM, Mazeron JJ, Marinello G, Raynal M, Huart J, Leung S, LeBourgeois JP, and Pierquin B
- Subjects
- Brachytherapy adverse effects, Humans, Necrosis epidemiology, Neoplasm Recurrence, Local, Radiation Injuries epidemiology, Radiotherapy Dosage, Skin pathology, Skin radiation effects, Carcinoma, Basal Cell radiotherapy, Carcinoma, Squamous Cell radiotherapy, Iridium Radioisotopes therapeutic use, Nose Neoplasms radiotherapy, Skin Neoplasms radiotherapy
- Abstract
Several implantation techniques useful for nasal skin carcinoma have been developed at the Henri Mondor Hospital in Créteil, France and are described in detail. Iridium 192 wires, 0.3 mm in diameter, are afterloaded into either supple plastic tubes or rigid needles implanted according to the rules of the Paris system. Dosimetry is performed by computer, based on either direct measurements of active lengths and spacing, orthogonal films or a tomogram oriented in the central plane of the implant. According to a recent review by the European Curietherapy Group of 468 implants, the optimal dose is 60 Gy. The overall failure rate was 2.6%. Indications for implantation and choice of technique, based on tumor size, site, and gross morphology are discussed.
- Published
- 1990
- Full Text
- View/download PDF
19. Definitive radiation treatment for early stage carcinoma of the soft palate and uvula: the indications for iridium 192 implantation.
- Author
-
Mazeron JJ, Marinello G, Crook J, Marin L, Mahot P, Raynal M, Calitchi E, Peynegre R, Ganem G, and Faraldi M
- Subjects
- Brachytherapy, Cobalt Radioisotopes, Humans, Iridium Radioisotopes, Radiotherapy adverse effects, Carcinoma, Squamous Cell radiotherapy, Mouth Neoplasms radiotherapy, Palatal Neoplasms radiotherapy, Uvula
- Abstract
From 1971 to 1984 59 T1 and T2 carcinomas of the soft palate and uvula were treated definitively by irradiation at the Henri Mondor hospital. Included are ten patients previously irradiated to the oropharyngeal area for either a carcinoma of the soft palate or another malignancy. Sixteen patients were treated by external irradiation alone, 14 by Iridium 192 implantation, and 29 by a combination of the two. Two techniques of implantation were used: the guide gutter technique (33 patients) and the plastic tube technique (10 patients). Clinically negative neck nodes (51/59) either received prophylactic telecobalt therapy (39/51) or were surveilled (12/51). Clinically involved nodes (8/59) were managed either by external irradiation alone (4/8) or combined with neck dissection (4/8). Local failure was 25% (4/16) after exclusive telecobalt therapy, 18% (5/19) after combined telecobalt therapy and implantation, and 0% (0/14) after Iridium 192 implantation alone. No local failures were seen with the plastic tube technique (0/10) as compared to 15% (5/33) for guide gutters. Only two nodal failures were observed (2/59: 3%). Crude 5-year disease-free survival was 33%. Severe complications were limited to one osteonecrosis, one soft tissue necrosis, and one partial palatal incompetence. Salivary impairment was reduced when implantation was used for part or all of the treatment. We recommend 45 Gy external radiation followed by 30 Gy from Iridium 192 implantation using the plastic tube method unless there has been prior oropharyngeal irradiation, in which case we give 60 Gy from implantation alone. For clinically negative neck nodes, we recommend 45 Gy prophylactic external neck irradiation. For clinically positive lymph nodes, this should be followed by either a 25 to 30 Gy boost to the involved nodes or a neck dissection.
- Published
- 1987
- Full Text
- View/download PDF
20. Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium 192.
- Author
-
Mazeron JJ, Crook J, Chopin D, Abbou CC, Le Bourgeois JP, Auvert J, and Pierquin B
- Subjects
- Adult, Aged, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Carcinoma, Transitional Cell radiotherapy, Carcinoma, Transitional Cell surgery, Combined Modality Therapy, Female, Humans, Iridium Radioisotopes therapeutic use, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Urinary Bladder surgery, Urinary Bladder Neoplasms radiotherapy, Urinary Bladder Neoplasms surgery, Carcinoma, Squamous Cell therapy, Carcinoma, Transitional Cell therapy, Urinary Bladder Neoplasms therapy
- Abstract
From 1971 to 1984, 85 patients with bladder carcinoma were treated conservatively at the Henri Mondor Hospital by a combination of short course of pre-operative external pelvic irradiation, iliac node dissection, partial cystectomy, and iridium 192 implantation. There were 79 transitional cell carcinomas (G1: 12, G2: 25, G3: 36, Gx: 6) and 6 squamous cell carcinomas. By clinical stage, based on endoscopic resection, there were 43 T1, 30 T2, 5 T3, and 7 Tx. After partial cystectomy the pathologic stage distribution was: 41 pT1, 31 pT2, and 13 pT3. Crude disease-free survival at 5 years is 72% for T1 tumors and 55% for T2, but overall only 16% of patients died of bladder carcinoma. Local failures were seen in 11.5% of T1 and 0% of T2 tumors, and second bladder tumors developed at a distance from the treated site in 11.5% of T1 and 7% of T2. There is a non significant trend for intravesical recurrences (both local failures and second tumors) to occur more frequently for G1 tumors (25%) than for G2 (16%) or G3 (7%). At 5 years 95% of disease-free survivors have a functioning bladder. Regional or distant metastases occurred in 54% of patients with pT3 tumors and 10% of those with pT1 or pT2; within each stage there was no apparent influence of grade on metastatic risk. The four patients with histologically positive iliac nodes received additional post-operative external pelvic irradiation; three died of metastases and one is disease free at 10 years. No abdominal scar recurrences were seen. Late complications occurred in 6% of the population. For T1 tumors we suggest modification of the described protocol, eliminating the pre-operative irradiation and the lymph node dissection. If there is no doubt as to the pathologic stage after complete endoscopic resection, iridium 192 implantation delivering a dose of 60 Gy, without partial cystectomy, may be sufficient management. By contrast, for T2 tumors, all elements of the protocol seem important to obtain optimal results.
- Published
- 1988
- Full Text
- View/download PDF
21. Combined external irradiation and interstitial implantation for T1 and T2 epidermoid carcinomas of base of tongue: the Creteil experience (1971-1981).
- Author
-
Crook J, Mazeron JJ, Marinello G, Martin M, Raynal M, Calitchi E, Faraldi M, Ganem G, Le Bourgeois JP, and Pierquin B
- Subjects
- Adult, Aged, Cobalt Radioisotopes therapeutic use, Female, Humans, Iridium Radioisotopes therapeutic use, Male, Middle Aged, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Radioisotope Teletherapy, Tongue Neoplasms radiotherapy
- Abstract
Forty-eight patients with T1 or T2 epidermoid carcinomas of the base of tongue were treated at the Henri Mondor Hospital between 1971 and 1981. Forty-one patients received moderate dose 60Co external beam irradiation (mean: 48.6 Gy) to the primary tumor and regional nodes, followed by an interstitial iridium 192 implant to the primary tumor (mean: 32 Gy). This completed the treatment for the 30 node negative patients, but those with clinically positive nodes were managed by either an additional electron beam boost to the involved nodes or a neck dissection. Seven tumors were treated exclusively by implantation to the base of tongue (mean: 63 Gy). Five-year crude disease-free survival is 50% with 35% of patients dying of recurrent disease. Definitive local control for T1 lesions is 85% (11/13) and for T2 is 71% (25/35). A dose response effect was observed with local control of 79% (26/33) obtained with a combined dose greater than or equal to 75 Gy, but only 50% (4/8) for less than or equal to 70 Gy. For N0 patients definitive regional control is 97% and for N1-3 is 89%. Minor or moderate soft tissue ulceration was observed in 12 patients, including 3 cases that progressed to osteonecrosis. None required surgical intervention. No correlation exists between necrosis and tumor size or total dose.
- Published
- 1988
- Full Text
- View/download PDF
22. Iridium 192 implantation of squamous cell carcinomas of the oropharynx.
- Author
-
Mazeron JJ, Crook J, Martin M, Peynegre R, and Pierquin B
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Palate, Soft, Retrospective Studies, Brachytherapy, Carcinoma, Squamous Cell radiotherapy, Iridium Radioisotopes therapeutic use, Palatal Neoplasms radiotherapy, Tongue Neoplasms radiotherapy, Tonsillar Neoplasms radiotherapy
- Abstract
From 1970 to 1984, 127 patients with T1 or T2 carcinomas of the oropharynx were treated with external irradiation to the primary tumor and neck nodes to a dose of 45 Gy, followed by a further 30 Gy delivered by an iridium 192 implant to the primary tumor. Patients with clinically positive nodes had either further neck irradiation using electrons or a neck dissection. Crude 5-year disease-free survival was 66% for tonsillar carcinomas, 43% for soft palate, and 51% for base of tongue. Local control was 98%, 85%, and 76%, respectively. Regional control was 97% for N0 patients and 88% for N1-3. Soft tissue ulceration occurred in 17 patients; all healed spontaneously. The high rate of local control achieved in these patients while preserving function and minimizing xerostomia supports the use of this approach.
- Published
- 1989
- Full Text
- View/download PDF
23. [Update on exclusive radiotherapy of T1 and T2 of the faucial arch].
- Author
-
Mazeron JJ, Crook J, Mahot P, Martin M, Raynal M, Faraldi M, Juvanon JM, Peynègre R, and Pierquin B
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy, Carcinoma, Squamous Cell pathology, Evaluation Studies as Topic, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Recurrence, Local, Carcinoma, Squamous Cell radiotherapy, Mouth Neoplasms radiotherapy, Pharyngeal Neoplasms radiotherapy
- Abstract
From April 1971 to October 1984, 71 patients with T1 or T2 tumors of the faucial arch were treated according to the following protocol: Telecobalt therapy to the primary site and to the neck nodes to a dose of 45 Gy. Brachytherapy to the primary site to a dose of 25 to 30 Gy using iridium 192. For node positive patients, boost dose to involved neck nodes with electrons, or radical neck dissection. Seven patients with T1N0 tumors were treated exclusively by 60 Gy iridium implantation. The crude disease free survival is 66% for the group of patients with tumors of the tonsillar region and 41% for those with tumors of the soft palate or uvula. Local control of tonsillar tumors was 98% while that of tumors of the soft palate was 85%. Regional control was 98% for the N0 group and 87% for the N1-3 group. Five cases of soft tissue ulceration were observed, all of which healed spontaneously within a few months. Less salivary impairment was seen than after treatment by external irradiation alone. While these promising results have encouraged the use of this protocol, the introduction of the plastic tube technique has expanded the indications to include almost all T1 and T2 tumors of the faucial arch without obvious extension to the base of tongue or retromolar trigone.
- Published
- 1987
24. Radiation therapy of carcinomas of the skin of nose and nasal vestibule: a report of 1676 cases by the Groupe Europeen de Curiethérapie.
- Author
-
Mazeron JJ, Chassagne D, Crook J, Bachelot F, Brochet F, Brune D, Brunin F, Bunescu U, Daly N, and Danczak S
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy, Carcinoma, Basal Cell pathology, Carcinoma, Squamous Cell pathology, Esthetics, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multicenter Studies as Topic, Neoplasm Recurrence, Local, Nose Neoplasms pathology, Radiotherapy, High-Energy, Retrospective Studies, Carcinoma, Basal Cell radiotherapy, Carcinoma, Squamous Cell radiotherapy, Nasal Cavity, Nose Neoplasms radiotherapy
- Abstract
A retrospective multicentric analysis of the results of irradiation of 1676 carcinomas of the skin of the nose and nasal vestibule was performed by the Groupe Européen de Curiethérapie (Tunis, May 1986). Overall local control was 93% with a minimum follow-up of 2 years. Local control is dependent on the tumor size (diameter less than 2 cm: 96%, 2-3.9 cm: 88%, greater than or equal to 4 cm: 81%), and tumor site (external surface of the nose: 94%, vestibule: 75%). Local control was independent of histology for smaller tumors, but for those larger than 4 cm, basal cell carcinomas were more frequently controlled than squamous cell carcinomas. Recurrent tumors are less frequently controlled than those being treated for the first time (88 vs. 95%). There were few complications and cosmetic results were generally satisfactory. The results of implantation, orthovoltage and megavoltage irradiation are compared with respect to local control, complication rate and cosmesis. Implantation is usually the treatment of choice for vestibular tumors but for those of the external surface the choice depends on the tumor diameter. Implantation and orthovoltage irradiation are equivalent for tumors less than 2 cm. For those from 2 to 3.9 cm, the results of orthovoltage irradiation may be satisfactory in a selected population but implantation is usually more suitable for tumors with rapidly changing contour.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1988
- Full Text
- View/download PDF
25. [Salvage irradiation of epidermoid carcinoma of the oropharynx by iridium 192].
- Author
-
Mazeron JJ, Langlois D, Crook J, Martin M, Raynal M, Peynègre R, Baillet F, and Pierquin B
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy adverse effects, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local radiotherapy, Brachytherapy methods, Carcinoma, Squamous Cell radiotherapy, Iridium Radioisotopes therapeutic use, Oropharyngeal Neoplasms radiotherapy, Pharyngeal Neoplasms radiotherapy
- Abstract
Between May 1971 and March 1982, 73 patients with either recurrent or subsequent squamous cell carcinomas arising in a previously irradiated oropharynx were treated using iridium 192 wires. Although local control was achieved in 72% of these patients, only 10 remained alive at 5 years (14%). Local control was best for tonsillar arch lesions (96%), while base of tongue and glosso-tonsillar sulcus tumors were controlled in only 60%. One of the two patients with a posterior pharyngeal wall lesion is alive and well at 5 years, while the other died of an unknown cause at 20 months. Salvage implantation produced soft tissue necrosis in 36% of base of tongue implants, but only 18% of those involving the tonsillar arch. Although one necrosis was fatal, the others were successfully managed medically. Since these results compare favorably with those of previously published series, we recommend re-irradiation with iridium 192 for recurrent or new malignancies arising in a previously irradiated oropharynx. For tonsillar arch lesions, brachytherapy is the treatment of choice while in the base of tongue, it is reasonable option.
- Published
- 1987
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.